Other

Immediate Release Melatonin for Parkinson's Disease

Mayo Clinic Florida, Jacksonville, FL
Targeting 2 different conditionsImmediate Release Melatonin +1 moreN/ARecruitingLed by Emir Festic, MD, MSResearch Sponsored by Mayo Clinic

Study Summary

This trial will compare the effectiveness of two types of melatonin supplements in people with Parkinson's disease and a sleep disorder.

Eligible Conditions
  • Parkinson's Disease
  • REM Sleep Behavior Disorder

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below
Select...
You have Parkinson's disease and experience rapid eye movement sleep behavior disorder.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and 4 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 4 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in sleep cycle

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Immediate Release Melatonin, Then Extended Release MelatoninExperimental Treatment2 Interventions
Subjects will receive immediate release melatonin 5 mg orally at 9 pm every night for 4 weeks. After a washout period of 2 weeks, they then receive extended release melatonin 5 mg orally at 9 pm every night for 4 weeks.
Group II: Extended Release Melatonin, Then Immediate Release MelatoninExperimental Treatment2 Interventions
Subjects will receive extended release melatonin 5 mg orally at 9 pm every night for 4 weeks. After a washout period of 2 weeks, they then receive immediate release melatonin 5 mg orally at 9 pm every night for 4 weeks.

Find a site

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,048 Previous Clinical Trials
3,484,685 Total Patients Enrolled
Emir Festic, MD, MSPrincipal Investigator
Mayo Clinic

Media Library

Extended Release Melatonin (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05307770 — N/A
Parkinson's Disease Research Study Groups: Immediate Release Melatonin, Then Extended Release Melatonin, Extended Release Melatonin, Then Immediate Release Melatonin
Parkinson's Disease Clinical Trial 2023: Extended Release Melatonin Highlights & Side Effects. Trial Name: NCT05307770 — N/A
Extended Release Melatonin (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05307770 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many human participants are partaking in this clinical experiment?

"Affirmative, the clinical trial is currently in search of participants. It was first announced on May 1st 2022 and its information was most recently updated on May 24th 2022. This medical study requires 50 enrollees from a single site."

Answered by AI

Is there still room available for volunteers in this research endeavor?

"Clinicaltrials.gov confirms that this experiment is recruiting volunteers, with the first posting taking place on May 1st 2022 and being revised as recently as May 24th of the same year."

Answered by AI
~13 spots leftby Apr 2024